Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M. Arance, Stephane Dalle, C. Lance Cowey, Michael Schenker, Jean Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O. Butler, Anna Marie Di Giacomo, Mark R. Middleton, Luis De la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael MillwardNikhil I. Khushalani, Paola Queirolo, Georgina V. Long, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Mario Mandalá

Research output: Contribution to journal › Article › peer-review

30 Citations (Web of Science)

Fingerprint

Dive into the research topics of 'Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria'. Together they form a unique fingerprint.

Medicine and Dentistry